Vascular age calculation and equivalent risk factors in HIV-infected patients obtained from the D:A:D risk equation

Abstract

Background

Vascular age is a concept that represents the hypothetical age of the cardiovascular system and might be an alternative way of expressing the cardiovascular risk of a patient. The Data Collection on Adverse Effects of Anti-HIV Drugs Study (D:A:D) developed a cardiovascular risk equation from a population of HIV-infected patients, incorporating exposure to individual antiretroviral therapy drugs and traditional classic cardiovascular risk factors.

Objectives

The aim of this study was to determine the vascular age calculated from the D:A:D equation, for HIV infected patients.

Methods

Vascular age was calculated according to its definition by using the D:A:D equation. The Poisson regression model used in the D:A:D equation is an exponential model to calculate the vascular age to match the exponent of the equation with the factors of a patient with the exponent of a subject with controlled risk factors.

Results

We obtained an equation that allows calculating the vascular age of a patient considering cardiovascular risk factors listed in the same D:A:D equation. From the equation, we have built a table for easy calculation of the vascular age and a table of cardiovascular risk equivalents.

Conclusions

Vascular age is a new concept derived from Framingham risk tables that can be calculated with other risk scales, such as D:A:D for HIV patients. The calculation of vascular age in HIV patients could be a useful tool for communicating cardiovascular risk and to improve the control of modifiable risk factors.

Keywords

HIV vascular age D:A:D equation

Get full access to this article

View all access options for this article.

References

Mary-Krause

Cotte

Simon

. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. Aids 2003; 17: 2479–2486.

Trian

. HIV infection and coronary heart disease: An intersection of epidemics. J Infect Dis 2012; 205(Suppl. 3): S355–S361.

Friis-Møller

Thiébaut

Reiss

. DAD study group. Predicting the risk of cardiovascular disease in HIV-infected patients: The data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil 2010; 17: 491–501.

D’Agostino

Sr Vasan

Pencina

. General cardiovascular risk profile for use in primary care: The Framingham Heart Study. Circulation 2008; 117: 743–753.

Cuende

Calaveras-Lagartos

. How to calculate vascular age with the SCORE project scales: A new method of cardiovascular risk evaluation. Eur Heart J 2010; 31: 2351–2358.

Cuende JI, Calvo PL and Cuende N. Equivalentes de riesgo cardiovascular: Otra forma de mirar las tablas de riesgo de Framingham. In: XVII Congreso de la Sociedad Castellano-Leonesa-Cántabra de Medicina Interna, Valladolid, 17–18 May 2002, http://www.socalmi.org/comunicaciones_1.htm (2002, accessed 24 February 2016).

Allan

Garrison

McCormack

. Comparison of cardiovascular disease risk calculators. Curr Opin Lipidol 2014; 25: 254–265.

Law

Friis-Møller

El-Sadr

. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: Comparison with observed events in the D:A:D Study. HIV Med 2006; 7: 218–230.

Estrada

Bernardino

Masiá

. Cardiovascular risk factors and lifetime risk estimation in HIV-infected patients under antiretroviral treatment in Spain. HIV Clin Trials 2015; 16: 57–65.

10.

Groenewegen

den Ruijter

Pasterkamp

. Vascular age to determine cardiovascular disease risk: A systematic review of its concepts, definitions, and clinical applications. Eur J Prev Cardiol 2016; 23: 264–274.

11.

Cuende

. Vascular age versus cardiovascular risk: Clarifying concepts. Rev Esp Cardiol (Engl Ed) 2016; 69: 243–246.

12.

Davies

Gompels

Johnston

. Mind the gap: Difference between Framingham heart age and real age increases with age in HIV-positive individuals – a clinical cohort study. BMJ Open 2013; 3: e003245–e003245.

13.

Reinsch

Neuhaus

Esser

. German Competence Network Heart Failure; German Competence Network for HIV/AIDS. Are HIV patients undertreated? Cardiovascular risk factors in HIV: Results of the HIV-HEART study. Eur J Prev Cardiol 2012; 19: 267–274.

14.

Maniar

Ellis

Asmuth

. HIV infection and atherosclerosis: Evaluating the drivers of inflammation. Eur J Prev Cardiol 2013; 20: 720–728.

15.

Friis-Møller

Ryom

Smith

. D:A:D study group. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. Eur J Prev Cardiol 2016; 23: 214–223.